ZA202204542B - Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine - Google Patents
Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amineInfo
- Publication number
- ZA202204542B ZA202204542B ZA2022/04542A ZA202204542A ZA202204542B ZA 202204542 B ZA202204542 B ZA 202204542B ZA 2022/04542 A ZA2022/04542 A ZA 2022/04542A ZA 202204542 A ZA202204542 A ZA 202204542A ZA 202204542 B ZA202204542 B ZA 202204542B
- Authority
- ZA
- South Africa
- Prior art keywords
- methylmorpholino
- chlorobenzyl
- triazol
- piperidin
- amine
- Prior art date
Links
- STWVLEKJQQRGMO-GUYCJALGSA-N 3-[4-[(2S,5S)-5-[(4-chlorophenyl)methyl]-2-methylmorpholin-4-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine Chemical compound ClC1=CC=C(C[C@@H]2N(C[C@@H](OC2)C)C2CCN(CC2)C=2NC(=NN=2)N)C=C1 STWVLEKJQQRGMO-GUYCJALGSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962905494P | 2019-09-25 | 2019-09-25 | |
| PL43126919 | 2019-09-25 | ||
| PCT/IB2020/058984 WO2021059220A1 (en) | 2019-09-25 | 2020-09-25 | Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202204542B true ZA202204542B (en) | 2023-01-25 |
Family
ID=73139065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2022/04542A ZA202204542B (en) | 2019-09-25 | 2022-04-22 | Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11746107B2 (https=) |
| EP (1) | EP4041726B8 (https=) |
| JP (1) | JP7697933B2 (https=) |
| KR (1) | KR20220069008A (https=) |
| CN (1) | CN114466845B (https=) |
| AU (1) | AU2020356534B2 (https=) |
| BR (1) | BR112022005420A2 (https=) |
| CA (1) | CA3155177A1 (https=) |
| ES (1) | ES3056105T3 (https=) |
| IL (1) | IL291569B2 (https=) |
| MX (1) | MX2022002881A (https=) |
| PH (1) | PH12022550713A1 (https=) |
| PL (1) | PL4041726T3 (https=) |
| TW (3) | TWI769532B (https=) |
| WO (1) | WO2021059220A1 (https=) |
| ZA (1) | ZA202204542B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022002881A (es) | 2019-09-25 | 2022-06-08 | Oncoarendi Therapeutics Sa | Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2802530B1 (fr) * | 1999-12-17 | 2002-02-22 | Sanofi Synthelabo | Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant |
| ATE354568T1 (de) * | 2000-08-08 | 2007-03-15 | Ortho Mcneil Pharm Inc | Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden |
| PE20142366A1 (es) * | 2012-05-30 | 2015-01-10 | Hoffmann La Roche | Compuestos triazolo como inhibidores de pde 10 |
| EP3082805B1 (en) * | 2013-12-20 | 2020-02-05 | Institute for Drug Discovery, LLC | Substituted amino triazoles, and methods using same |
| US9440953B2 (en) | 2014-12-19 | 2016-09-13 | OncoArendi Therapeutics Sp. z o.o. | Substituted amino triazoles useful as acidic mammalian chitinase inhibitors |
| GB201513740D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| PL415078A1 (pl) * | 2015-09-04 | 2017-03-13 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków |
| MX2022000306A (es) | 2019-07-15 | 2022-03-11 | Oncoarendi Therapeutics Sa | Amino triazoles sustituidos utiles como inhibidores de quitinasa. |
| MX2022002881A (es) | 2019-09-25 | 2022-06-08 | Oncoarendi Therapeutics Sa | Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina. |
-
2020
- 2020-09-25 MX MX2022002881A patent/MX2022002881A/es unknown
- 2020-09-25 TW TW109133211A patent/TWI769532B/zh active
- 2020-09-25 KR KR1020227009777A patent/KR20220069008A/ko active Pending
- 2020-09-25 JP JP2022519042A patent/JP7697933B2/ja active Active
- 2020-09-25 PL PL20803247.4T patent/PL4041726T3/pl unknown
- 2020-09-25 TW TW111121583A patent/TWI849432B/zh active
- 2020-09-25 BR BR112022005420A patent/BR112022005420A2/pt unknown
- 2020-09-25 CA CA3155177A patent/CA3155177A1/en active Pending
- 2020-09-25 TW TW113127475A patent/TWI892762B/zh active
- 2020-09-25 CN CN202080067709.7A patent/CN114466845B/zh active Active
- 2020-09-25 ES ES20803247T patent/ES3056105T3/es active Active
- 2020-09-25 US US17/032,232 patent/US11746107B2/en active Active
- 2020-09-25 PH PH1/2022/550713A patent/PH12022550713A1/en unknown
- 2020-09-25 AU AU2020356534A patent/AU2020356534B2/en active Active
- 2020-09-25 IL IL291569A patent/IL291569B2/en unknown
- 2020-09-25 EP EP20803247.4A patent/EP4041726B8/en active Active
- 2020-09-25 WO PCT/IB2020/058984 patent/WO2021059220A1/en not_active Ceased
-
2022
- 2022-04-22 ZA ZA2022/04542A patent/ZA202204542B/en unknown
-
2023
- 2023-07-17 US US18/222,679 patent/US12319677B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022549863A (ja) | 2022-11-29 |
| PL4041726T3 (pl) | 2026-02-23 |
| EP4041726B1 (en) | 2025-09-17 |
| EP4041726A1 (en) | 2022-08-17 |
| CN114466845B (zh) | 2024-12-17 |
| IL291569B1 (en) | 2024-12-01 |
| EP4041726C0 (en) | 2025-09-17 |
| TW202448877A (zh) | 2024-12-16 |
| IL291569A (en) | 2022-05-01 |
| PH12022550713A1 (en) | 2024-02-12 |
| IL291569B2 (en) | 2025-04-01 |
| JP7697933B2 (ja) | 2025-06-24 |
| WO2021059220A1 (en) | 2021-04-01 |
| CA3155177A1 (en) | 2021-04-01 |
| EP4041726B8 (en) | 2025-11-26 |
| US20210147401A1 (en) | 2021-05-20 |
| CN114466845A (zh) | 2022-05-10 |
| TW202126644A (zh) | 2021-07-16 |
| TWI769532B (zh) | 2022-07-01 |
| US20240025889A1 (en) | 2024-01-25 |
| BR112022005420A2 (pt) | 2022-06-21 |
| AU2020356534A1 (en) | 2022-05-19 |
| TWI849432B (zh) | 2024-07-21 |
| ES3056105T3 (en) | 2026-02-18 |
| US11746107B2 (en) | 2023-09-05 |
| US12319677B2 (en) | 2025-06-03 |
| MX2022002881A (es) | 2022-06-08 |
| AU2020356534B2 (en) | 2026-04-09 |
| KR20220069008A (ko) | 2022-05-26 |
| TWI892762B (zh) | 2025-08-01 |
| TW202237594A (zh) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202101006B (en) | Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate | |
| ZA202103223B (en) | Process for the preparation of (s)-nicotin from myosmine | |
| IL258862A (en) | Derivatives Ann .- [2- (1-Benzylphipridine-4-yl) ethyl] -4- (Pirazine-2-yl) -pipridine-1-carboxamide and compounds related as muscarinic receptor 4 antagonists for the treatment of neurological diseases | |
| IL291384A (en) | Process for preparing 5-(fluoro-4-imino-3-methyl)-1-tosyl-3,4 dihydropyrimidine -(1h)-one | |
| ZA202204542B (en) | Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine | |
| DK3057967T3 (da) | Ny krystallin form for 2-{3-[2-(1-{[3,5-bis(difluormethyl)-1h-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}-3-chlorphenylmethansulfonat | |
| HUE066520T2 (hu) | Eljárás 5-bróm-2-(3-klór-piridin-2-il)-2H-pirazol-3-karbonsav szintézis közttermékének elõállítására | |
| PL3953339T3 (pl) | Proces otrzymania 1-deoksy-1-metyloamino-d-glucitolu 2-(3,5-dichlorofenylo)-6-benzoksazolokarboksylanu | |
| SI3298008T1 (sl) | Kristalinična oblika spojine (S)-3-(4-(5-(2-ciklopentil-6-metoksi-piridin-4-IL)-(1,2,4)oksadiazol-3- IL)-2-etil-6-metil-fenoksi)-propan 1,2-diol | |
| UY37222A (es) | PROCEDIMIENTO PARA LA PREPARACIÓN DE DERIVADOS DE 1-FENILO-1,2,4-TRIAZOL SUSTITUIDOS POR 5-HIdroxIalQUILO | |
| EP3541796A4 (en) | 4 - ((6- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H | |
| EP3541801A4 (en) | 4- (6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H | |
| EP3233824A4 (en) | (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations | |
| EP3976843A4 (en) | Method for recovering gold from refractory materials | |
| EP3541797A4 (en) | 4 - ((6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H | |
| EP3233079A4 (en) | (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations | |
| IL289664A (en) | Process for the preparation of 2-(phenylimino)-1, 3- thiazolin-4-ones | |
| PH12017500124A1 (en) | Azole benzene derivative and crystalline form thereof | |
| PH12017500123A1 (en) | Crystal of azole benzene derivative | |
| EP3166404A4 (en) | Improved process for preparation of 4-(1-(4-(perfluoroethoxy)phenyl)-1h-1,2,4-triazol-3-yl)benzoyl azide | |
| IL289651A (en) | A process for the preparation of 2-(phenylimino)-3,1-thiazolidin-4-ones | |
| IL307590A (en) | 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1 -(((S)-OXETAN-2-YL)MTHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY | |
| PH12017501985A1 (en) | Use of 2-{3-[2-(1-{[3,5-bis(difluoromethyl)-1h-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}-3-chlorophenyl methanesulfonate | |
| HK40131421A (en) | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide | |
| UA97633U (xx) | 3-((2-хлоретил)тіо)-5-(4-метоксифеніл)-1н-1,2,4-триазол, що проявляє гіпоглікемічну активність |